Cbl negatively regulates erythropoietin-induced growth and survival signaling through the proteasomal degradation of Src kinase

Blood Cells Mol Dis. 2014 Dec;53(4):211-8. doi: 10.1016/j.bcmd.2014.06.005. Epub 2014 Jul 29.

Abstract

We examined the biological functions of the gene Cbl in erythropoietin (EPO) signaling using Cbl-deficient F-36P human erythroleukemia cells by the introduction of the Cbl siRNA expression vector. Knockdown of Cbl promoted EPO-dependent proliferation and survival of F-36P cells, especially at a low concentration of EPO (0.01U/mL), similar to serum concentrations of EPO in healthy volunteers (0.005-0.04U/mL). We found that Src was degraded mainly by the proteasomal pathway because the proteasome inhibitor MG-132 but not the lysosome inhibitor NH4Cl suppressed the EPO-induced degradation of Src in F-36P cells and that knockdown of Cbl inhibited EPO-induced ubiquitination and degradation of Src in F-36P cells. The experiments using the Src inhibitor PP1 and co-expression experiments further confirmed that Cbl and the kinase activity of Src are required for the EPO-induced ubiquitination of Src. In addition, the co-expression experiments and in vitro kinase assay demonstrated that the EPO-induced tyrosine phosphorylation and ubiquitination of Cbl were dependent on the kinase activity of Src but not Jak2. Thus, Cbl negatively regulates EPO signaling mainly through the proteasome-dependent degradation of Src, and the E3 ligase activity of Cbl and its tyrosine phosphorylation are regulated by Src but not Jak2.

Keywords: Cbl; Erythropoietin; Proteasome; Src; Ubiquitination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ammonium Chloride / pharmacology
  • Antineoplastic Agents / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Erythropoietin / metabolism
  • Erythropoietin / pharmacology*
  • Gene Expression Regulation
  • Humans
  • Janus Kinase 2 / genetics
  • Janus Kinase 2 / metabolism
  • Leupeptins / pharmacology
  • Lymphocytes / cytology
  • Lymphocytes / drug effects*
  • Lymphocytes / metabolism
  • Phosphorylation / drug effects
  • Proteasome Endopeptidase Complex / drug effects
  • Proteasome Endopeptidase Complex / metabolism
  • Proteolysis
  • Proto-Oncogene Proteins c-cbl / antagonists & inhibitors
  • Proto-Oncogene Proteins c-cbl / genetics*
  • Proto-Oncogene Proteins c-cbl / metabolism
  • Proto-Oncogene Proteins pp60(c-src) / antagonists & inhibitors
  • Proto-Oncogene Proteins pp60(c-src) / genetics*
  • Proto-Oncogene Proteins pp60(c-src) / metabolism
  • Pyrazoles / pharmacology
  • Pyrimidines / pharmacology
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Signal Transduction
  • Ubiquitination

Substances

  • 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine
  • Antineoplastic Agents
  • EPO protein, human
  • Leupeptins
  • Pyrazoles
  • Pyrimidines
  • RNA, Small Interfering
  • Ammonium Chloride
  • Erythropoietin
  • Proto-Oncogene Proteins c-cbl
  • JAK2 protein, human
  • Janus Kinase 2
  • Proto-Oncogene Proteins pp60(c-src)
  • Proteasome Endopeptidase Complex
  • CBL protein, human
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde